We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Reviva Pharmaceuticals Holdings, Inc. is one of the oversold stocks to invest in.
TheFly reported on April 9 that Maxim Group downgraded RVPH from Buy to Hold. The firm pointed to ongoing weakness in the share price following the company’s one-for-20 reverse stock split completed on March 9. It noted that although recent funding may help advance a second Phase 3 study of brilaroxazine, additional capital will still be required. With the stock trading below the $1.00 NASDAQ compliance level, the analyst also highlighted heightened delisting risk alongside continued financing concerns as key factors behind the downgrade.
Earlier on March 30, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) reported its full-year 2025 financial results along with key business and development updates. The company posted a net loss of approximately $19.9 million, or $5.48 per share, compared with a $29.9 million loss in 2024. Cash and cash equivalents totaled about $14.4 million as of December 31, 2025.
15 States with the Best Healthcare in the US
During 2025 and early 2026, RVPH completed multiple equity offerings, including $10.0 million raised in March 2026, with total cash expected to support operations into Q1 2027. The update also highlighted regulatory feedback from the FDA recommending a second Phase 3 trial for brilaroxazine in schizophrenia, alongside continued advancement of RECOVER-2 planned for mid-2026. Additional progress included patent expansion efforts, completed manufacturing and nonclinical studies, and ongoing
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company developing therapies for central nervous system, inflammatory, respiratory, and cardiometabolic diseases. Its lead drug candidate, brilaroxazine, targets schizophrenia and other neuropsychiatric disorders.
READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.
